Interleukin 28B gene polymorphisms in hepatitis c virus-related cryoglobulinemic vasculitis

Journal of Rheumatology

Volumn 41, Issue 1, 2014, Pages 91-98

  Sansonno, Domenico ^a   Russi, Sabino ^a   Serviddio, Gaetano ^b   Conteduca, Vincenza ^b   D'Andrea, Giovanna ^b   Sansonno, Loredana ^b   Pavone, Fabio ^a   Lauletta, Gianfranco ^a   Mariggiò, Maria Addolorata ^a   Dammacco, Franco ^a  

^a UNIVERSITY OF BARI MEDICAL SCHOOL   (Italy)

^b UNIVERSITY OF FOGGIA   (Italy)

Author keywords

Antiviral therapies; Cryoglobulinemic vasculitis; HCV infection; Interleukin 28B; Single nucleotide polymorphism

Indexed keywords

INTERLEUKIN 28B; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2A PLUS RIBAVIRIN; PEGINTERFERON ALPHA2B; PEGINTERFERON ALPHA2B PLUS RIBAVIRIN;

ADULT; AGED; ANTIVIRAL THERAPY; ARTICLE; B LYMPHOCYTE; CELL EXPANSION; CLONAL VARIATION; COHORT ANALYSIS; CONTROLLED STUDY; CRYOGLOBULINEMIC VASCULITIS; DISEASE ASSOCIATION; FEMALE; GENE FREQUENCY; GENE REARRANGEMENT; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; GENOTYPING TECHNIQUE; HEPATITIS C VIRUS GENOTYPE 1; HOMOZYGOSITY; HUMAN; IL 28B GENE; KIDNEY; MAJOR CLINICAL STUDY; MALE; NONHODGKIN LYMPHOMA; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SINGLE NUCLEOTIDE POLYMORPHISM; TAQ MAN ALLELIC DISCRIMINATION; TREATMENT RESPONSE; VASCULITIS;

ANTIVIRAL THERAPIES; CRYOGLOBULINEMIC VASCULITIS; HCV INFECTION; INTERLEUKIN 28B; SINGLE-NUCLEOTIDE POLYMORPHISM;

ALLELES; ANTIVIRAL AGENTS; CRYOGLOBULINEMIA; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; INTERLEUKINS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; TREATMENT OUTCOME; VASCULITIS; VIRAL LOAD;

EID: 84891755561     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.130527     Document Type: Article

References (36)

1. Heim MH. Innate immunity and HCV. J Hepatol 2013;58:564-74.
2. Sansonno D, Dammacco F. Hepatitis C virus, cryoglobulinaemia, and vasculitis: immune complex relations. Lancet Infect Dis 2005;5:227-36.
3. Agnello V. The aetiology of mixed cryoglobulinaemia associated with hepatitis C virus infection. Scand J Immunol 1995;42:179-84.
4. Dammacco F, Sansonno D, Han JH, Shyamala V, Cornacchiulo V, Iacobelli AR, et al. Natural interferon-alpha versus its combination with 6-methyl-prednisolone in the therapy of type II mixed cryoglobulinemia: a long-term, randomized, controlled study. Blood 1994;84:3336-43.
5. Cacoub P, Saadoun D, Limal N, Sene D, Lidove O, Piette JC. PEGylated interferon alfa-2b and ribavirin treatment in patients with hepatitis C virus-related systemic vasculitis. Arthritis Rheum 2005;52:911-5.
6. Ferenci P, Fried MW, Shiffman ML, Smith CI, Marinos G, Goncales FL Jr, et al. Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin. J Hepatol 2005;43:425-33.
7. Kanwal F, Hoang T, Spiegel BM, Eisen S, Dominitz JA, Gifford A, et al. Predictors of treatment in patients with chronic hepatitis C infection-role of patient versus nonpatient factors. Hepatology 2007;46:1741-9.
8. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, et al. Genetic variation in IL28B predicts hepatitis C treatmentinduced viral clearance. Nature 2009;461:399-401.
9. Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, Sakamoto N, et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 2009;41:1105-9.
10. Suppiah V, Moldovan M, Ahlenstiel G, Berg T, Weltman M, Abate ML, et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 2009;41:1100-4.
11. Rauch A, Kutalik Z, Descombes P, Cai T, Di Iulio J, Mueller T, et al. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology 2010;138:1338-45, 45 e1-7.
12. Boesecke C, Rockstroh JK. Treatment of acute hepatitis C infection in HIV-infected patients. Curr Opin HIV AIDS 2011;6:278-84.
13. McCarthy JJ, Li JH, Thompson A, Suchindran S, Lao XQ, Patel K, et al. Replicated association between an IL28B gene variant and a sustained response to pegylated interferon and ribavirin. Gastroenterology 2010;138:2307-14.
14. Deuffic-Burban S, Castel H, Wiegand J, Manns MP, Wedemeyer H, Mathurin P, et al. Immediate vs. delayed treatment in patients with acute hepatitis C based on IL28B polymorphism: a model-based analysis. J Hepatol 2012;57:260-6.
15. Dammacco F, Tucci FA, Lauletta G, Gatti P, De Re V, Conteduca V, et al. Pegylated interferon-alpha, ribavirin, and rituximab combined therapy of hepatitis C virus-related mixed cryoglobulinemia: a long-term study. Blood 2010;116:343-53.
16. Sansonno D, De Vita S, Iacobelli AR, Cornacchiulo V, Boiocchi M, Dammacco F. Clonal analysis of intrahepatic B cells from HCV-infected patients with and without mixed cryoglobulinemia. J Immunol 1998;160:3594-601.
17. Sansonno D, Lauletta G, De Re V, Tucci FA, Gatti P, Racanelli V, et al. Intrahepatic B cell clonal expansions and extrahepatic manifestations of chronic HCV infection. Eur J Immunol 2004;34:126-36.
18. Levine JW, Gota C, Fessler BJ, Calabrese LH, Cooper SM. Persistent cryoglobulinemic vasculitis following successful treatment of hepatitis C virus. J Rheumatol 2005;32:1164-7.
19. Landau DA, Saadoun D, Halfon P, Martinot-Peignoux M, Marcellin P, Fois E, et al. Relapse of hepatitis C virus-associated mixed cryoglobulinemia vasculitis in patients with sustained viral response. Arthritis Rheum 2008;58:604-11.
20. Lauletta G, Russi S, Conteduca V, Sansonno L, Dammacco F, Sansonno D. Impact of cryoglobulinemic syndrome on the outcome of chronic HCV infection. A 15-year prospective study. Medicine 2013;92:245-56.
21. Dammacco F, Sansonno D, Piccoli C, Tucci FA, Racanelli V. The cryoglobulins: an overview. Eur J Clin Invest 2001;31:628-38.
22. Urban TJ, Thompson AJ, Bradrick SS, Fellay J, Schuppan D, Cronin KD, et al. IL28B genotype is associated with differential expression of intrahepatic interferon-stimulated genes in patients with chronic hepatitis C. Hepatology 2010;52:1888-96.
23. Rothman KJ. No adjustments are needed for multiple comparisons. Epidemiology 1990;1:43-6.
24. Hosmer DW, Lemeshow S. Applied logistic regression. New York: Wiley & Sons; 1989.
25. Gragnani L, Piluso A, Giannini C, Caini P, Fognani E, Monti M, et al. Genetic determinants in hepatitis C virus-associated mixed cryoglobulinemia: role of polymorphic variants of BAFF promoter and Fcgamma receptors. Arthritis Rheum 2011;63:1446-51.
26. Charles ED, Brunetti C, Marukian S, Ritola KD, Talal AH, Marks K, et al. Clonal B cells in patients with hepatitis C virus-associated mixed cryoglobulinemia contain an expanded anergic CD21low B-cell subset. Blood 2011;117:5425-37.
27. Saadoun D, Resche-Rigon M, Thibault V, Piette JC, Cacoub P. Antiviral therapy for hepatitis C virus-associated mixed cryoglobulinemia vasculitis: a long-term followup study. Arthritis Rheum 2006;54:3696-706.
28. Feng B, Eknoyan G, Guo ZS, Jadoul M, Rao HY, Zhang W, et al. Effect of interferon-alpha-based antiviral therapy on hepatitis C virus-associated glomerulonephritis: a meta-analysis. Nephrol Dial Transplant 2012;27:640-6.
29. Piluso A, Giannini C, Fognani E, Gragnani L, Caini P, Monti M, et al. Value of IL28B genotyping in patients with HCV-related mixed cryoglobulinemia: results of a large, prospective study. J Viral Hepat 2013;20:e107-14.
30. Dammacco F, Sansonno D, Piccoli C, Racanelli V, D'Amore FP, Lauletta G. The lymphoid system in hepatitis C virus infection: autoimmunity, mixed cryoglobulinemia, and Overt B-cell malignancy. Semin Liver Dis 2000;20:143-57.
31. Cerutti A, Puga I, Cols M. Innate control of B cell responses. Trends Immunol 2011;32:202-11.
32. Bochud PY, Bibert S, Kutalik Z, Patin E, Guergnon J, Nalpas B, et al. IL28B alleles associated with poor hepatitis C virus (HCV) clearance protect against inflammation and fibrosis in patients infected with non-1 HCV genotypes. Hepatology 2012;55:384-94.
33. Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364:2405-16.
34. Poordad F, McCone J Jr., Bacon BR, Bruno S, Manns MP, Sulkowski MS, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011;364:1195-206.
35. Seo SJ, Fields ML, Buckler JL, Reed AJ, Mandik-Nayak L, Nish SA, et al. The impact of T helper and T regulatory cells on the regulation of anti-double-stranded DNA B cells. Immunity 2002;16:535-46.
36. Landau DA, Rosenzwajg M, Saadoun D, Trébeden-Negre H, Klatzmann D, Cacoub P. Correlation of clinical and virologic responses to antiviral treatment and regulatory T cell evolution in patients with hepatitis C virus-induced mixed cryoglobulinemia vasculitis. Arthritis Rheum 2008;58:2897-907.